Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Immuneering

Immuneering
2008 FOUNDED
M&A STATUS
Corporate LATEST DEAL TYPE
$20M LATEST DEAL AMOUNT
1 INVESTORS
Description

Provider of advisory services to pharmaceutical companies intended to the development of new drugs for treatment. The company's services are focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis, enabling clients in the healthcare sectors to manufacture drugs to counteract several critical diseases.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 245 Main Street, Second Floor
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Immuneering’s full profile, request a free trial.

Immuneering Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Corporate 27-Jan-2020 $20M 0000 Completed Generating Revenue
2. Later Stage VC (Series A) 16-Dec-2019 0000 0000 Completed Generating Revenue
1. Merger/Acquisition 30-Sep-2015 $60M 00000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Immuneering Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Immuneering Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambry Genetics Private Equity-Backed Aliso Viejo, CA 000 00000 000000&0 00000
00000000000 Venture Capital-Backed Helsinki, Finland 00 00.000 0000000000 0 00.000
00000000000000 Corporate Backed or Acquired Bangalore, India 00.000 000000000 00.000
000000 00000000 Venture Capital-Backed San Francisco, CA 0 00.00 000000000 00.00
0000 00 0000 Accelerator/Incubator Backed Houston, TX 000000000000
To view this company’s complete list of competitors, request access »

Immuneering Executive Team (5)

Name Title Board
Seat
Contact
Info
Benjamin Zeskind Ph.D Co-Founder, Chief Executive Officer and Board Member
Rebecca Kusko Ph.D Chief Strategy Officer
Brett Hall Chief Scientific Officer
Bob Carpenter Co-Founder & Board Member
Scott Barrett MD Chief Medical Officer

Immuneering Board Members (2)

Name Representing Role Since Contact
Info
Bob Carpenter Immuneering Co-Founder & Board Member 000 0000
Joseph Kekst Self Board Member 000 0000